Skip to main content
Log in

Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma — a comparison of L-TAE with Farmorubicin and L-TAE with Adriamycin (second cooperative study)

  • Session I: Treatment for Operable Patients Surgery and Combined Modalities
  • Lipiodol-Transcatheterarteria Embolization, Adriamycin Farmorubicin, Analyzed Endpoints
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

A randomized clinical trial comparing L-TAE with Farmorubicin (FARM) and L-TAE with Adriamycin (ADR) in the treatment of hepatocellular carcinoma was conducted from October 1989 through December 1990. In all, 192 hospitals participated in this study and 117 patients were entered. The patients were randomly allocated to group A (L-TAE+FARM) or group B (L-TAE+ADR). There was no significant intergroup difference in background factors. Additional treatment consisting of repeated TAE or surgery was given to 66 patients. Four factors were analyzed in this study: the percentage of reduction in tumor size, the change in the AFP level, lipiodol accumulation, and survival. None of these factors differed significantly between the two groups. The final evaluation of this study will be based on differences in survival after a long-term follow-up. Toxic effects manifested less frequently in group A than in group B, and the decrease in the platelet count in the peripheral blood was significantly lower in group A than in group B. These results suggest that FARM exerts a more favorable effect than does ADR in the treatment of hepatocellular carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Epirubicin Study Group for Hepatocellular Carcinoma (1987) Intra-arterial administration of epirubicin in the treatment of nonresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 19: 183

    Google Scholar 

  2. Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, Kawarada Y, Kusano M, Kubo Y, Kuroda C, Sakata Y, Shimamura Y, Jinno K, Takahashi A, Takayasu K, Tamura K, Nagasue N, Nakanishi Y, Makino M, Masuzawa M, Mikuriya S, Monden M, Yumoto Y, Mori T, Oda T, Cooperative Study Group for Liver Cancer Treatment of Japan (1992) Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma — a comparison of lipiodoltranscatheter arterial embolization with and without Adriamycin (first cooperative study). Cancer Chemother Pharmacol (in press)

  3. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, Hasegawa H, Hirohashi S (1987) Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 162: 345

    Google Scholar 

  4. Uchida H, Ohishi H, Matsuo N, Nishimine K, Ohue S, Nishimura Y, Maeda M, Yoshioka T (1990) Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol 13: 140

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okamura, J., Kawai, S., Ogawa, M. et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma — a comparison of L-TAE with Farmorubicin and L-TAE with Adriamycin (second cooperative study). Cancer Chemother. Pharmacol. 31 (Suppl 1), S20–S24 (1992). https://doi.org/10.1007/BF00687099

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00687099

Keywords

Navigation